A clinical textbook

Hepatology 2018

5. HBV virology

Maura Dandri, Jörg Petersen


The human hepatitis B virus (HBV) is a small-enveloped DNA virus causing acute and chronic hepatitis. Despite the availability of a safe and effective vaccine, HBV infection still represents a major global health burden, with about 240 million people chronically infected worldwide (Schweitzer 2015). Many epidemiological and molecular studies have shown that chronic HBV infection represents the main risk factor for hepatocellular carcinoma development (Shepard 2006, Lok 2004, Pollicino 2011). The rate for chronicity is approximately 5% in adult infections, but it reaches 90% in neonatal infections. HBV transmission occurs vertically and horizontally via exchange of body fluids. In serum, up to 1012 HBV genome equivalents per mL serum can be found. Although HBV does not induce direct cytopathic effects under normal infection conditions (Wieland 2004, Thimme 2003), liver damage (fibrosis, cirrhosis, and eventually hepatocellular carcinoma) is believed to be induced by the ongoing immune reaction and a consistent inflammation of the liver (McMahon 2009, Chisari 2007, Dandri 2012).

HBV is the prototype member of the Hepadnaviridae family, which are the smallest known DNA-containing, enveloped animal viruses. Characteristic of HBV is its high tissue- and species-specificity, as well as a unique genomic organisation with asymmetric mechanism of replication (Nassal 2015). Since all hepadnaviruses use a reverse transcriptase to replicate their genome, they are considered distantly related to retroviruses. Despite decades of research and significant progress in understanding the molecular virology of HBV, important steps of the infection have not yet been clarified. Nevertheless, the discovery of the cellular receptor (Yan 2012) and the establishment of innovative infection models and molecular techniques have opened up new possibilities to investigate specific steps of the lifecycle as well as the organisation and activity of the covalently closed circular DNA (cccDNA), the viral minichromosome that serves as the template of HBV transcription in the nucleus of the infected hepatocytes, enabling maintenance of chronic HBV infection (Levrero 2009).

Taxonomic classification and genotypes

The Hepadnaviridae form their own taxonomic group as their biological characteristics are not observed in any other viral family. Based on host and phylogenetic differences, the family of Hepadnaviridae contains two genera: the orthohepadnaviruses infecting mammals, and the avihepadnaviruses that infect birds. To date, orthohepadnaviruses have been found in human (HBV), woodchuck (WHV) (Korba 1989), ground squirrel (GSHV), arctic squirrel (ASHV) and woolly monkey (WMHBV) (Lanford 1998). Avihepadnaviruses include duck HBV (DHBV) (Mason 1980), heron HBV (HHBV) (Sprengel 1988), Ross’s goose HBV, snow goose HBV (SGHBV), stork HBV (STHBV) (Pult 2001) and crane HBV (CHBV) (Roggendorf 2007, Funk 2007, Dandri 2005b, Schaefer 2007). Moreover, three unique hepadnavirus species antigenically related to human HBV and capable of infecting human hepatocytes were also identified in bats (Drexel 2013). The relatedness of these viruses to HBV suggests that bats might constitute ancestral sources of primate hepadnaviruses.

Due to the lack of proofreading activity of the viral polymerase, misincorporation of nucleotide mutations occurs during viral replication. This has led to the emergence of eight HBV genotypes, A-H, which differ in more than 8% of the genome, as well as different subgenotypes, which differ by at least 4% (Fung and Lok 2004, Guirgis 2010). The HBV genotypes have different geographic distribution (Liaw 2010), with predominance of genotype A in northwestern Europe, North and South America, genotype B and C in Asia and genotype D in eastern Europe and in the Mediterranean basin. The less diffuse remaining genotypes are mostly found in West and South Africa (genotype E), in Central and South America (genotypes F and H), while genotype G has been detected in France and in the US (Pujol 2009). The phylogenetic tree of HBV genomes is reviewed elsewhere (Schaefer 2007).

HBV structure and genomic organisation

Three types of viral particles can be visualised in the infectious serum by electron microscopy: the infectious virions and the subviral particles. The infectious virus particles are the so-called Dane particles (Dane 1970), have a spherical, double-shelled structure of 42–44 nm containing a single copy of the viral DNA genome, covalently linked to the terminal protein of the virus. A hallmark of HBV infection is the presence of two additional types of particles, the spheres and the filaments, which are exclusively composed of hepatitis B surface proteins and host-derived lipids (Glebe 2007). Since they do not contain viral nucleic acids, the subviral particles are non-infectious. The spherical structures measure around 22 nm in diameter, while the filaments are of similar width, but of variable lengths (Figure 1).

The viral membrane contains three viral surface proteins and is acquired by the virus during budding into the endoplasmic reticulum (ER), whereas the viral particles are transported via the secretory pathways through the ER and Golgi. The surface proteins are named the preS1 (or large), the preS2 (or middle) and the S (or small), which bears the HBsAg. The surface proteins are produced in quantities largely exceeding the amount needed for the assembly of HBV virions and because of their self-assembly abilities, they are secreted abundantly as empty subviral particles (SVPs). As with nearly all enveloped viruses, HBV particles and SVPs also contain proteins of host origin (Glebe 2007, Urban 2010).

The HBV genome consists of a partially double-stranded relaxed circular DNA of approximately 3200 nucleotides in length, varying slightly from genotype to genotype, that in concert with the core protein (HBcAg) forms the nucleocapsids (Nassal 2015). Within the Dane particle the negative strand of the viral DNA is present in full-length, carrying the complete genetic information. In contrast, the positive strand spans only approximately two-thirds of the genome in length, whilst its 3’ end is variable in size (Summers 1988, Lutwick 1977). The viral polymerase is covalently bound to the negative strand by a phosphotyrosine bond. At the 5’ end of the positive strand a short RNA oligomer originating from the pre-genomic (pg) RNA residually remains bound covalently after the viral DNA synthesis. The negative strand also contains a small redundancy of 8–9 nucleotides in length on both the 5’ end and the 3’ end, named the R region. These redundant structures are essential for viral replication (Seeger 1986, Nassal 2015).

Figure 1. Schematic representation of the HBV virion and non-infectious empty subviral particles (filaments and spheres). Within the nucleocapsid (HBcAg, shown in black) is depicted the partial double-stranded viral genome (rcDNA) covalently linked to the terminal protein of reverse transcriptase. The presence and distribution of the three surface proteins L (preS1 or large), M (preS2 or middle) and S (small) are shown both on HBV and subviral particles (adapted from Glebe 2007).

The HBV genome displays four major open reading frames (ORFs) that are organised in a unique and highly condensed way (Block 2007). As shown in Figure 2, all ORFs are in an identical orientation, partially overlap and are encoded by the negative strand. On the genome, 6 start codons, four promoters and two transcription-enhancing elements have been identified. The four major ORFs are: I) the preS/S, encoding the three viral surface proteins; II) the precore/core, encoding both the core protein, essential for the formation of the nucleocapsid, and the non-structural pre-core protein, also known as the secreted e-antigen (HBeAg); III) the pol ORF of the viral polymerase, which possesses reverse transcriptase, DNA polymerase and RNase H activities, and the terminal protein; and IV) the X ORF, coding for the small regulatory X protein, which has been shown to be essential in vivo to establish productive viral infection (Zoulim 1994, Lucifora 2011) and is capable of transactivating numerous cellular and viral genes. Moreover, recent studies indicated that HBx also promotes the degradation of specific viral proteins to enhance HBV replication (Decorsiere 2016). Characteristic of the 4 major HBV ORFs is that they utilise a single common polyadenylation signal motif (Nassal 2015). Thus, all RNA transcripts are polyadenylated and capped.

Figure 2. Genome organisation and transcripts of the human hepatitis B virus. The outer thin lines represent the viral transcripts that initiate at different sites, under the control of distinct promoters, but are all terminated after a common polyadenylation site. The RNA signal on the terminally redundant pgRNA is indicated as a hairpin. The thick lines represent the rcDNA form of the genome as present in infectious virions. The 5’ end of the minus-strand DNA is covalently linked to the terminal protein of the polymerase. The 5’ end of the incomplete plus-strand DNA is constituted by an RNA oligo derived from the 5’ end of pgRNA. DR1 and DR2 indicate the direct repeats. The inner arrows indicate the open reading frames (adapted from Nassal 2015).

HBV structural and non-structural proteins

The three surface proteins (L, M, and S) are encoded from one open reading frame (PreS/S) which contains three start codons (one for the large, one for the middle and one for the small protein) but promotes the transcription of 2 mRNAs of 2.4 and 2.1 Kb, named preS and S RNAs (Urban 2014). Notably, the preS/S ORF entirely overlaps with the polymerase open reading frame (Nassal 2015). The three HBV envelope proteins share the C-terminal domain of the S-protein, while the M- and L-protein display progressive N-terminal extensions of 55 and, genotype-dependent, 107 or 118 amino acids (preS2 and preS1). The small envelope protein contains the hepatitis B surface antigen (HBsAg). In virions the stoichiometric ratio of L, M and S is about 1:1:4, while the more abundantly secreted non-infectious subviral particles (SVPs) contain only traces of L-protein (Urban 2014). The envelope proteins are co-translationally inserted into the ER membrane, where they aggregate, bud into the ER lumen, and are secreted by the cell, either as 22 nm subviral envelope particles (SVPs) or as 42 nm infectious virions (Dane particles), after having enveloped the DNA-containing nucleocapsids. The surface proteins of mammalian Hepadnaviridae have been shown to be N- and O-glycosylated (Schmitt 2004). These glycosylations have been shown to be responsible for proper secretion of progeny viral particles. During synthesis, the preS1 domain of L is myristoylated and translocated through the ER. This modification and the integrity of the first 77 amino acids of preS1 have been shown to be essential for infectivity (Glebe 2005, Schulze 2010). Both spherical and filamentous SVPs are secreted into the blood of infected individuals in a 103–106-fold excess relative to the infectious particles. The biological function of the excess of SVPs in patients is not clear. It was suggested that SVPs might absorb the neutralising antibodies produced by the host and hence increase the ability of the infectious particles to reach the hepatocytes. It has also been suggested that SVPs contribute to create a state of immune tolerance, which is a precondition for highly productive persistent infection (Dandri 2012).

In the cytoplasm, the core protein dimerises and self-assembles to form an icosahedral nucleocapsid. The full-length core protein is 183 amino acids in length and consists of an assembly domain and a nucleic acid-binding domain, which plays an active role in binding and packaging of the pregenomic RNA together with the viral polymerase, and thus enables the RT polymerase/RNA complex to initiate reverse transcription within the newly forming nucleocapsids (Kann 1994, Kann 1999, Daub 2002, Nassal 2015). The core protein can be phosphorylated by several kinases. This step along with the presence of the viral polymerase is important for the specific packaging of the pgRNA (Kann 1999, Porterfield 2010).

The viral polymerase is the single enzyme encoded by the HBV genome and is an RNA-dependent DNA polymerase with RNase H activity. The HBV polymerase consists of three functional domains and a so-called spacer region; the terminal protein (TP) is located at its N-terminal domain, and serves as a primer for reverse transcription of the pgRNA into a negative-strand DNA (Zoulim 1994). The spacer domain separates the terminal protein from the polymerase domains (Nassal 2015).

Despite the occurrence of nucleotide mutations due to the lack of proofreading capacity of the HBV polymerase, the peculiar genomic organisation of HBV, where most of the genes overlap, imposes stronger constraints on the amino acid sequence, which significantly reduces the occurrence of mutations in the absence of strong selective pressures. Nevertheless, it has been shown that antiviral therapy with nucleoside analogues can promote the selection of nucleotide mutations within conserved domains of the reverse transcriptase, which leads to mutations on the amino acid sequence of the envelope proteins. Changes on the HBsAg structure may lead to reduced binding of anti-HBs antibodies, and hence, they may favour the selection of antibody escape mutants (Harrison 2006).

Besides the production of large amounts of empty SVPs, HBV produces and secretes a non-particulate form of the nucleoprotein, the precore protein, or HBeAg, which is not required for viral infection or replication, but appears to act as a decoy for the immune system, and hence, has tolerogenic functions in promoting viral persistence in the neonates of viremic mothers (Chen 2005, Visvanathan 2006). The precore and core proteins are translated from two distinct RNA species that have different 5’ initiation sites: the precore RNA and the pgRNA. Indeed, the precore transcript, which also contains the full core gene, encodes a signal sequence that directs the precore protein to the lumen of the endoplasmic reticulum, where it is post-translationally processed. Here, the precore protein undergoes N- and C-terminal cleavage to produce the mature HBeAg form (p17), which is then secreted as a monomeric protein. Interestingly, 20 to 30% of the mature protein is retained in the cytoplasm, where it may antagonise TLR signalling pathways and so contribute to the suppression of the host innate immune responses (Lang 2011). As an important marker for active viral replication, the HBeAg is widely used in molecular diagnostics (Chen 2005, Hadziyannis 2006).

The X protein is a multifunctional regulatory protein with transactivating and pro-apoptotic potential, which can modify several cellular pathways (Bouchard 2004) and act as a carcinogenic cofactor (Kim 1991, Dandri 1996, Slagle 1996). Numerous DNA transfection experiments have shown that over-expression of the X protein (HBx) causes transactivation of a wide range of viral elements and cellular promoters (Bouchard 2004). In vitro studies have shown that HBx can affect various cytoplasmic signal transduction pathways by activating the Src kinase, Ras/Raf/MAP kinase, members of the protein kinase C, as well as Jak1/STAT (Bouchard 2001, Bouchard 2004). Furthermore, in vitro binding studies show that HBx can regulate the proteasome function, and thus, may control the degradation of cellular and viral proteins (Zhang 2004), as well as mitochondrial function, by altering its transmembrane potential, and that HBx can modulate calcium homeostasis (Bouchard 2001, Yang 2011). Although the exact role of HBx in the context of HBV infection has not been fully elucidated, several independent studies obtained using the woodchuck model (Zoulim 1994), human liver chimeric mice (Tsuge 2010) and HepaRG™ cells (Lucifora 2011), have convincingly shown that HBx is required to initiate HBV replication and to maintain virion productivity. Notably, these studies indicated that despite the establishment of comparable cccDNA amounts, transcription of HBV RNAs was dramatically impaired in cells inoculated with HBV X-minus mutants, indicating that HBx is essential to promote cccDNA-driven viral transcription. These findings are also in agreement with data showing that HBx is recruited to the cccDNA minichromosome, where it was shown to participate in epigenetic control of cccDNA-driven HBV transcription (Belloni 2009, Levrero 2009). Of note, recent studies provide evidence that HBx can mediate the degradation of the ‘structural maintenance of chromosomes’ (Smc) complex Smc5/6 (Decorsiere 2016, Murphy 2016). Among the host factors that are known to interact with HBx, the damaged DNA binding protein 1 (DDB1) was identified in previous studies, although the function of such interaction remained elusive. The study of Decorsiere et al. shows that HBx uses DDB1 as an adaptor protein to interact with an E3 ubiquitin ligase enzyme named CRL4, which is a component of the ubiquitin–proteasome system. Several viruses are known to exploit the ubiquitin–proteasome system to ensure productive infection. Being involved in chromosome organisation and DNA repair, the smc5/6 complex probably binds to the cccDNA acting as a host factor suppressing viral transcription. Thus, ubiquitination and degradation of the Smc5/6 complex by the cell’s proteasome machinery, which was demonstrated to occur both in HBV infected human hepatocytes in vitro and in humanised mice in vivo, represents a new mechanism by which HBx can contribute to HBV replication.

Most HBV-related HCC show the integration of HBV DNA sequences including the X gene (Brechot 2004, Pollicino 2011, Lupberger 2007). Although HBV integrated forms are frequently rearranged and hence not compatible with the expression of functional proteins, HBx sequences deleted in the C-terminal portion have been frequently detected in tumoural cells (Iavarone 2003). In virus-associated cancers, viral proteins have been shown to participate in epigenetic alterations by disturbing the host DNA methylation system. Interestingly, a study suggested that the HBV regulatory X protein is a potent epigenetic modifying factor in the human liver, which can modulate the transcription of DNA methyltransferases required for normal levels of genomic methylation and maintenance of hypomethylation of tumour suppressor genes (TSGs) (Park 2007). HBx-promoted hypermethylation of TSGs suggests a novel mechanism by which this promiscuous transactivating protein may accelerate hepatocarcinogenesis.

The HBV replication cycle

During the last 30 years, the generation of various HBV-transfected human hepatoma cell lines and the use of related HBV viruses – including the duck hepatitis B virus (DHBV) and the woodchuck hepatitis virus (WHV) – have significantly contributed to elucidate many steps of the hepadnavirus replication cycle (Dandri 2013). Nevertheless, the lack of efficient in vitro infection systems and of easily accessible animal models has significantly hindered the identification of mechanisms and cellular factors mediating viral entry and uncoating in human hepatocytes. Although primary hepatocytes remain permissive in vitro for only a short time after plating, the availability of primary hepatocytes from tree shrews (Tupaia belangeri) for infection studies with HBV and the closely-related woolly monkey hepatitis B virus (WMHBV) (Kock 2001), and the discovery of a human hepatoma cell line (HepaRG) able to gain susceptibility for HBV infection upon induction of differentiation in vitro (Gripon 2002), have expanded our possibilities to functionally dissect the HBV entry process (Schulze 2010).

The first step in HBV infection was shown to involve a non-cell-type specific primary attachment to the cell-associated heparan sulfate proteoglycans (Schulze 2007). This first reversible attachment step is then followed by an irreversible binding of the virus to a specific hepatocyte-specific receptor (Urban 2014). Using mutational analysis, important determinants for infectivity were identified within the HBV envelope proteins. These include 75 amino acids of the preS1 domain of the HBV L-protein, its myristoylation and the integrity of a region in the antigenic loop of the S domain (Gripon 2005, Engelke 2006, Meier 2013). It has also been shown that HBV and HDV infection can be blocked by a small lipopeptide (MyrB) containing the same aminoacid sequence of the preS1 domain of the HBV-L protein (Petersen 2008, Lütgehetmann 2012). Although cell polarisation, in addition to the differentiation status of the hepatocytes, was shown to play an essential role in the infection process (Schulze 2011), the identity of the receptor has remained a mystery for many years. Thus, the recent identification of the cellular receptor that allows hepatitis B and Delta viruses to enter primary human liver cells, was a major finding. By using a method called zero-length photo cross-linking and tandem affinity purification, the preS1 peptide was seen to specifically interact with a sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter localised to the basolateral membrane of highly differentiated primary hepatocytes (Yan 2012). NTCP mediates the transport of conjugated bile acids and some drugs from portal blood to the liver. Based on the discovery that NTCP functions as viral entry receptor by interacting with the large surface protein of HBV, cell lines susceptible to HBV infection have been recently established and first studies indicated that both HBV and HDV infection can be established in a significant proportion of HepG2 cells stably transfected with the human NTCP (Yan 2012, Nkongolo 2013). Although large amounts of input viruses (MOI >1000) are still necessary to achieve HBV infection in these culture systems, the availability of in vitro assays permitting investigation of the early steps of infection as well as rapid screening of new anti-HBV agents has opened new opportunities in HBV research. Recent in vitro studies showed that HBV entry is inhibited by cyclosporins and oxysterols, which are known to bind to NTCP, in hNTCP-transfected hepatoma cells (Nkongolo 2013, Watashi 2013). Binding of the preS1 domain of the HBV envelope to the cellular receptor NTCP was also recently shown to limit its function, thus altering the hepatocellular uptake of bile salts and the expression profile of genes of the bile acid metabolism (Oehler 2014). Future studies will be needed to evaluate the consequences that the described metabolic alterations may have on other metabolic pathways, liver disease progression and on drug-drug interactions (Urban 2014).

Despite the importance of having discovered the functional cellular receptor mediating HBV entry, additional hepatocyte-specific and species-specific factors appear to be involved in the HBV infection process, as infection rates and virion productivity are generally low in NTCP expressing human cell lines. Intriguingly, establishment of transient HDV infection could be described in murine cells engineered to express the human NTCP, whereas HBV infection establishment failed in NTCP-expressing mouse hepatocytes (Li 2014, He 2015). Since HBV and HDV utilise the same envelope proteins for cell entry, additional downstream species-specific factors appear responsible for these discrepancies. As a consequence, no transgenic mice permissive for HBV infection are available. Upon binding to the cell membrane, two possible entry pathways have been proposed. Experimental evidence suggests that HBV can be either involved in an endocytosis process, followed by the release of the nucleocapsid from endocytic vesicles, or HBV may enter the hepatocytes after fusion of the viral envelope at the plasma membrane. As soon as the viral nucleocapsids are released into the cytoplasm, the relaxed circular partially double-stranded DNA (rcDNA) with its covalently linked polymerase needs to enter the cell nucleus in order to convert the rcDNA genome into a covalently closed circular form (cccDNA) (Nassal 2015). Previous studies indicated that the viral capsids are transported via microtubules to the nuclear periphery (Rabe 2006). The accumulation of the capsids at the nuclear envelope would then facilitate interactions with nuclear transport receptors and adaptor proteins of the nuclear pore complex (Kann 1999). Although immature capsids may remain trapped within the nuclear baskets by the pore complexes, the mature capsids eventually disintegrate, permitting the release of both core capsid subunits and of the viral DNA polymerase complexes, which diffuse into the nucleoplasm (Schmitz 2010).

Although the mechanism of cccDNA formation remains largely unknown, the establishment of productive HBV infection requires the removal of the covalently attached viral polymerase and completion of the positive-strand by the cellular replicative machinery to form the supercoiled cccDNA molecule, which is then incorporated into the host chromatin and serves as the template of viral transcription and replication (Nassal 2015, Newbold 1995). Because of similarities between rcDNA and cellular topoisomerase-DNA adducts that are repaired by tyrosyl-DNA-phosphodiesterase (TDP) 1 or TDP2, recent studies have provided evidence that HBV indeed uses these cellular enzymes to release the P protein from the rcDNA and thus initiates cccDNA biogenesis (Königer 2014). Unlike the provirus DNA of retroviruses, the cccDNA does not need to be incorporated into the host genome. Nevertheless, integration of HBV DNA sequences does occur, particularly in the course of hepatocyte turnover and in the presence of DNA damage, as has been shown in cell culture (Dandri 2002) and in the woodchuck system (Petersen 1998, Summers 2004, Mason 2005).

Disguised as a stable non-integrated minichromosome (Bock 1994, Bock 2001, Levrero 2009, Tropberger 2015), the cccDNA uses the cellular transcriptional machinery to produce all viral RNAs necessary for protein production and viral replication, which takes place in the cytoplasm after reverse transcription of an over-length pregenomic RNA (pgRNA) (Figure 3).

Figure 3. The HBV lifecycle. Upon hepatocyte infection the nucleocapsid is released into the cytoplasm and the rcDNA transferred to the cell nucleus where it is converted into the cccDNA minichromosome. After transcription of the viral RNAs, the pgRNA is encapsidated and reverse-transcribed by the HBV polymerase. Through Golgi and ER apparatus the core particles acquire the envelope and are secreted. Via viral entry and retransporting of the newly synthesised HBV DNA into the cell nucleus, the cccDNA pool can be amplified.

Experimental DHBV infection studies indicate that the cccDNA can be formed not only from incoming virions, but also from newly synthesised nucleocapsids, which instead of being enveloped and secreted into the blood, are transported into the nucleus to ensure accumulation, and later maintenance, of the cccDNA pool (Zoulim 2005b, Nassal 2015). According to this scenario, multiple rounds of infection are not needed to establish a cccDNA pool in infected duck hepatocytes. Moreover, expression of the DHBV viral large surface (LS) protein was shown to induce a negative-feedback mechanism, whereby the accumulation of the LS protein would be fundamental to shut off the cccDNA amplification pathway and redirect the newly synthesised rcDNA-containing nucleocapsids to envelopment and extracellular secretion (Kock 2010). Although this peculiar nuclear re-entry mechanism has been clearly demonstrated for the duck HBV (Summers 1991, Wu 1990) and a high copy number of cccDNA molecules is generally detected in chronically infected ducks and woodchucks (1 to 50 copies/cell) (Zhang 2003, Dandri 2000), lower cccDNA intrahepatic loads are generally determined in human liver biopsies obtained from chronically HBV-infected patients (median 0.1 to 1 cccDNA copy/cell) (Werle-Lapostolle 2004, Wong 2004, Laras 2006, Volz 2007, Wursthorn 2006, Lutgehetmann 2008) and in chronically HBV-infected human-liver chimeric uPA-SCID mice (Petersen 2008, Lutgehetmann 2011, Lutgehetmann 2010), suggesting that different viral and host mechanisms may control cccDNA dynamics and cccDNA pool size in human infected hepatocytes (Levrero 2009). One elegant study showed that HBV converts the rcDNA into cccDNA less efficiently than DHBV in the same human cell background (Kock 2010).

Although the formation of the cccDNA minichromosome is essential to establish productive infection, studies performed in humanised mice indicate that this step is achieved initially only in a minority of human hepatocytes (Volz 2013). Indeed, three weeks postinfection, the intrahepatic cccDNA load is very low (approximately 1 copy/50 human hepatocytes) and only sporadic cells stain HBcAg positive, while within eight weeks the majority of human hepatocytes become infected. Thus, several weeks appear to be necessary for HBV to spread among human hepatocytes in vivo, even in the absence of adaptive immune responses.

HBV polymerase inhibitors do not directly affect cccDNA activity and various in vitro and in vivo studies support the notion that the cccDNA minichromosome is very stable in quiescent hepatocytes (Moraleda 1997, Dandri 2000, Dandri 2005, Lutgehetmann 2010). Thus, the significant decrease in cccDNA levels (approximately 1 log10 reduction) generally determined after one year of therapy with polymerase inhibitors (Werle-Lapostolle 2004) is supposed to derive from the lack of sufficient recycling of viral nucleocapsids to the nucleus, due to the strong inhibition of viral DNA synthesis in the cytoplasm, and less incoming viruses from the blood. Nevertheless, cccDNA depletion is expected to require many years of nucleos(t)ide drug administration. Thus, despite the absence of detectable viraemia, the persistence of the cccDNA minichromosome within the infected liver is responsible for the failure of viral clearance and the relapse of viral activity after cessation of antiviral therapy with polymerase inhibitors in chronically infected individuals. Furthermore, if viral suppression is not complete, the selection of resistant variants escaping antiviral therapy is likely to occur (Zoulim 2005, Zoulim 2009). Resistant HBV genomes can be archived in infected hepatocytes when nucleocapsids produced in the cytoplasm by reverse transcription and containing resistant mutants are transported into the nucleus and added to the cccDNA pool. Under antiviral pressure, these variants will coexist with wild-type cccDNA molecules and function as templates for the production and possibly further selection of replication-competent resistant mutants, which will spread to other hepatocytes and, eventually may even replace the wild-type cccDNA molecules in the liver (Zoulim 2006, Zoulim 2009).

During chronic HBV infection immune-mediated cell injury and compensatory hepatocyte proliferation may favour cccDNA decline and selection of cccDNA-free cells (Mason 2005, Lütgehetmann 2010). Notably, studies with the duck model show that antiviral therapy with polymerase inhibitors induces a greater cccDNA reduction in animals displaying higher hepatocyte proliferation rates (Addison 2002). cccDNA decrease was also determined in chronically WHV-infected woodchuck hepatocytes when cell turnover was induced in vitro by addition of cellular growth factors and viral replication was suppressed by adefovir (Dandri 2000). Furthermore, the identification of uninfected cccDNA negative cell clones containing traces of infection in the form of viral integration indicates that cccDNA clearance without cell destruction can occur in chronically infected woodchucks (Mason 2005). Thus, in chronic infection, killing of hepatocytes may be instrumental not only to eliminate infected cells but also to induce hepatocyte proliferation, which in turn, may favour cccDNA loss (Dandri 2005, Lutgehetmann 2010). On the other hand, studies have shown that very low levels of cccDNA can persist indefinitely, possibly explaining lifelong immune responses to HBV despite clinical resolution of HBV infection (Rehermann 1996).

As mentioned previously, the cccDNA acts chemically and structurally as an episomal DNA with a plasmid-like structure, which is organised as a minichromosome by histone and non-histone proteins (Bock 1994, Bock 2001, Newbold 1995). Hence its function is regulated, similarly to the cellular chromatin, by the activity of various nuclear transcription factors, including transcriptional coactivators, repressors and chromatin-modifying enzymes (Levrero 2009, Belloni 2012, Tropberger 2015). Congruent with the fact that HBV infects hepatocytes, nearly all elements regulating viral transcription have binding sites for liver-specific transcription factors (Levrero 2009, Quasdorff 2008). Nevertheless, although a number of factors regulating viral transcription are known, the exact molecular mechanisms regulating HBV transcription are still poorly defined. Both messenger and pregenomic RNAs are transported into the cytoplasm, where they are respectively translated or used as the template for progeny genome production. Thus, the transcription of the pgRNA is the critical step for genome amplification and determines the rate of HBV replication. Of note, antiviral cytokines such as IFN α were shown to have the capacity to repress cccDNA transcription (Belloni 2012), as well as to promote its partial degradation (Lucifora 2014). Such findings point out the important role that immune modulating factors may play in reducing cccDNA loads and activity. Thus, identification of the factors affecting stability and transcriptional activity of the cccDNA in the course of infection and under antiviral therapy may assist in the design of new therapeutic strategies aimed at silencing and eventually depleting the cccDNA reservoir (Nassal 2015).

The next crucial step in HBV replication is the specific packaging of pgRNA plus the reverse transcriptase into new capsids. The pgRNA bears a secondary structure – named the ε structure - that is present at both the 5’ and the 3’ ends. The ε hairpin loops at the 5’ end are first recognised by the viral polymerase and act as the initial packaging signal (Bartenschlager 1992). Binding of polymerase to the RNA stem-loop structure ε initiates packaging of one pgRNA molecule and its reverse transcription. The first product is single-stranded (ss) DNA of minus polarity; due to its unique protein priming mechanism, its 5’ end remains covalently linked to the polymerase. The pgRNA is concomitantly degraded, except for its 5’ terminal (approximately 15 to 18 nucleotides which serve as primer for plus-strand DNA synthesis), resulting in rcDNA. The heterogeneous lengths of the plus-strand DNAs generated by capsid-assisted reverse transcription may result from a non-identical supply of dNTPs inside individual nucleocapsids at the moment of their enclosure by the dNTP impermeable envelope. This predicts that intracellular cores produced in the absence of envelopment should contain further extended positive DNAs. Alternatively, space restrictions in the capsid lumen could prevent plus-strand DNA completion; in this view, further plus-strand elongation after infection of a new cell might destabilise the nucleocapsid and thus be involved in genome uncoating (Nassal 2015).

The final replication step, the assembly and release of HBV Dane particles, is also not fully understood. The envelopment of the DNA-containing nucleocapsids requires a balanced coexpression of the S and L proteins in order to recruit the nucleocapsid to the budding site. Moreover, the release of infectious viral particles was shown to occur via multivesicular bodies (MVBs), whereas the release of subviral particles (SVPs) proceeds via the general secretory pathway (Hoffmann 2013). Although the role of the envelope proteins in regulating the amplification of cccDNA in HBV is not well-characterised, recent studies indicate that the lack of expression of the envelope proteins increase cccDNA levels, while coexpression of the envelope proteins not only favours the secretion of viral particles, but also limits the completion of the plus-strand (Lentz 2011).

Notably, recent studies pointed out that in addition to HBV DNA, pregenomic RNA encapsidated and enveloped in virus-like particles is also found in the serum of chronically HBV-infected patients (van Bömmel 2015; Wang 2016). Moreover, the study of Wang et al. indicated that the release of pgRNA-containing particles seems to accompany that of DNA-containing virions under normal conditions, whereas the amount of pgRNA-containing particles was shown to increase after blocking the reverse transcription activity of the HBV polymerase with nucleotide/nucleoside analogues (NUCs) in vitro and in transgenic mice. In contrast to NUC therapy, a study in HBV-infected human liver chimeric mice indicated that administration of peg-IFNα decreased the levels of both serum HBV DNA and pgRNA (Giersch 2016). Moreover, this study showed that levels of serum pgRNA correlated with levels of pgRNA and cccDNA determined intrahepatically, thus suggesting that measurements of serum pgRNA may serve as a suitable serological marker to determine the persistence of active cccDNA molecules in the liver of infected patients (Giersch 2016).

Animal models of HBV infection

Because of the narrow host range and the lack of easily accessible and robust in vitro infection systems the study of HBV biology has been limited. Consequently researchers have attempted to establish animal models and cell culture systems that are permissive for HBV replication and at least partially reproduce some stages of HBV infection and can be used, e.g., for the preclinical testing of novel antiviral drugs.

Most of the progress in HBV research is based on infection studies performed with the two most commonly used HBV-related animal viruses: DHBV, which infects Peking ducks (Mason 1980) and WHV (Summers 1978), which infects the Eastern American woodchuck (Marmota monax).

One of the major advantages of the DHBV model is that domestic Peking ducks can be used under normal laboratory conditions and DHBV-permissive primary hepatocytes from ducklings or embryos are easily accessible. Furthermore, ducks show very high infectivity rates in vivo (Jilbert 1996) with high levels of DHBV replication and antigen expression. However, in contrast to mammalian hepadnaviruses, DHBV infection is cleared within a few days postinfection if the virus is not transmitted vertically. The DHBV genome is also smaller than that of the mammalian hepadnaviruses and shares little primary nucleotide sequence homology (40%) with HBV. Furthermore, DHBV infection is usually not associated with liver disease and development of hepatocellular carcinoma (HCC). Nevertheless, the duck model was widely used in preclinical trials (Zimmerman 2008, Reaiche 2010, Chayama 2011) and has contributed substantially to elucidate the hepadnaviral replication scheme (Mason 1982, Summers 1988, Delmas 2002).

In vitro and in vivo studies with woodchuck hepatitis B virus (WHV) have been fundamental in the preclinical evaluation of antiviral drugs now in use for treatment of HBV infection (Moraleda 1997, Tennant 1998, Mason 1998, Block 1998, Dandri 2000, Korba 2004, Menne 2005, Fletcher 2015). This is due to the fact that WHV is more similar to HBV in terms of genomic organisation than the avian hepadnaviruses. Experimental infection of newborn woodchucks almost invariably leads to chronic infection, whereas most animals infected at older ages develop acute hepatitis that results in an efficient immune response leading to viral clearance.

Since acute and chronic WHV infections in woodchucks show serological profiles similar to those of HBV infection in humans, the woodchuck system has provided important information about factors involved in the establishment of virus infection, replication and viral persistence (Lu 2001). Virtually all WHV chronic carrier woodchucks succumb to HCC 2–4 years post infection. Like in human HCC, regenerative hepatocellular nodules and hepatocellular adenomas are characteristically observed in WHV-infected woodchuck livers (Korba 2004). Proto-oncogene activation by WHV DNA integration has been observed frequently and is thought to play an important role in driving hepatocarcinogenesis in woodchucks, often activating a member of the myc family by various mechanisms (Tennant 2004). Viral integration is commonly found in woodchucks even after resolution of transient infection with WHV (Summers 2003), while its frequency increases dramatically in chronically infected animals (Mason 2005). Interestingly, WHV viral integration was used as a genetic marker to follow the fate of infected hepatocytes during resolution of transient infection in woodchucks (Summers 2003) and to estimate the amount of cell turnover occurring in the course of chronic infection (Mason 2005). Experimental infection studies in woodchucks also demonstrated that WHV mutants that lacked the X gene were unable or severely impaired to replicate in vivo (Chen 1993, Zoulim 1994, Zhang 2001). The woodchuck model of virally induced HCC has been used to test chemoprevention of HCC using long-term antiviral nucleoside therapy and for the development of new imaging agents for the detection of hepatic neoplasms by ultrasound and magnetic resonance imaging (Tennant 2004).

One main difference between human and rodent hepatitis B resides in the absence of associated cirrhosis in woodchuck and squirrel livers, even after prolonged viral infection (Buendia 1998). It is possible that the rapid onset of hepatocyte proliferation following liver damage in rodents does account for this discrepancy. One general disadvantage for using woodchucks is that they are genetically heterogeneous animals, difficult to breed in captivity and to handle in a laboratory setting. Nevertheless, the woodchuck model has greatly contributed in advancing our understanding of the pathogenesis of HBV infection.

Although HBV infects humans exclusively, it can be used to infect chimpanzees experimentally and, to a certain extent, tupaia, the Asian tree shrew (Baumert 2005). Chimpanzees were the first animals found to be susceptible to HBV infection (Barker 1973) and played an important role in the development of vaccines and in the evaluation of the efficacy of therapeutic antibodies (Ogata 1999, Dagan 2003). Though chimpanzees are not prone to develop chronic liver disease (Gagneux 2004), they provide an ideal model for the analysis of early immunological events of HBV acute infection and pathogenesis (Guidotti 1999). Infection experiments with chimpanzees showed that the majority of viral DNA is eliminated from the liver by non-cytolytic mechanisms that precede the peak of T cell infiltration (Guidotti 1999). T cell depletion studies in chimpanzees also indicate that the absence of CD8 positive cells greatly delays the onset of viral clearance (Thimme 2003). Chimpanzees have been used for preclinical testing of preventive and therapeutic vaccines (Will 1982, Guidotti 1999, Kim 2008, Murray 2005). Nonetheless, the large size, the strong ethical constraints and the high costs of chimpanzees severely limit their use for research purposes.

The tree shrew species Tupaia belangeri has been analysed for the study of HBV both in vitro and in vivo, taking advantage of the adaptability of these non-rodent mammals to the laboratory environment (Baumert 2005, von Weizsacker 2004). Inoculation of tree shrews with HBV positive human serum was shown to result in viral DNA replication in their livers, HBsAg secretion into the serum, and production of antibodies to HBsAg and HBeAg (Walter 1996). Although experimental infection of tree shrew with HBV infectious serum is not highly efficient, productive HBV infection was successfully passed through five generations of tree shrews and was specifically blocked by immunisation with hepatitis B vaccine (Yan 1996a). Interestingly, the development of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and/or aflatoxin B1 was reported (Yan 1996b). Whereas experimental infection of tree shrews causes only a mild, transient infection with low viral titres, primary hepatocytes isolated from them turned out to be a valuable alternative source of HBV-permissive cells (von Weizsacker 2004). More recently, the woolly monkey hepatitis B virus (WMHV) was isolated from a woolly monkey (Lagothrix lagotricha), an endangered new world primate (Lanford 1998). Interestingly, it has been shown that primary tupaia hepatocytes are susceptible to infection with WMHBV (Kock 2001, Dandri 2005a), providing a useful and more accessible alternative system for studying the early steps of hepadnaviral infection in vitro (Schulze 2011) and in vivo (Petersen 2008).

Because of the different limitations encountered using chimpanzees and models based on HBV-related viruses, recent developments have focused on using the natural target of HBV infection: the human hepatocyte. However, primary human hepatocytes are not easy to handle, cannot be propagated in vitro and their susceptibility to HBV infection is generally low and highly variable. Furthermore, cultured cells may respond differently to the infection than hepatocytes in the liver. The generation of mice harbouring human chimeric livers offered new possibilities to overcome some of these limitations (Dandri 2013).

Two major models are currently available: the urokinase-type plasminogen activator (uPA) transgenic mouse (Rhim 1994) and the knockout fumarylacetoacetate hydrolase (FAH) mouse (Azuma 2007). In both systems, the absence of adaptive immune responses permits the engraftment of transplanted xenogenic hepatocytes, while the presence of transgene-induced hepatocyte damage creates the space and the regenerative stimulus necessary for the transplanted cells to repopulate the mouse liver. Both models permit the establishment of HBV infection, which can then persist for the lifespan of the chimeric mouse (Dandri 2001, Bissig 2010). While mouse hepatocytes do not support HBV infection, human chimeric mice can be efficiently infected by injecting infectious serum derived from either patients or chimeric mice. Furthermore, genetically engineered viruses created in cell culture can be used to investigate phenotype and in vivo fitness of distinct HBV genotypes and variants (Tsuge 2005). Within the mouse liver human hepatocytes maintain a functional innate immune system and respond to stimuli induced by exogenously applied human IFNα (Belloni 2012). The lack of an adaptive immune system and the undetectable responsiveness of mouse liver cells to human IFNα make the model ideal to exploit the capacities of HBV to interfere with pathways of the innate antiviral response in human hepatocytes (Lutgehetmann 2011), as well as to assess the efficacy of new therapeutic approaches (Petersen 2008, Volz 2013). Moreover, humanised chimeric mice can be superinfected or simultaneously infected with different human hepatotropic viruses, such as HDV (Lütgehetmann 2012, Giersch 2014) and HCV (Hiraga 2009) to investigate the mechanisms of viral interference and response to antiviral treatment in the setting of coinfection.


Addison WR, Walters KA, Wong WW, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002;76:6356-63.

Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25:903-10.

Barker LF, Chisari FV, McGrath PP, et al. Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 1973;127(6):648-62.

Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. Embo J 1992;11:3413-20.

Baumert TF, Yang C, Schurmann P, et al. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology 2005;41(2):247-56.

Belloni L, Allweiss, L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012: 122(2):529-37.

Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 2009;106:19975-9.

Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924-30.

Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 2007;11:685-706.

Block TM, Lu X, Mehta AS, et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998;4:610-4.

Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-29.

Bock CT, Schwinn S, Locarnini S, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001;307:183-96.

Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004;78:12725-34.

Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001;294:2376-8.

Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127(5 Suppl 1):S56-61.

Buendia MA. Hepatitis B viruses and cancerogenesis. Biomed Pharma-cother 1998;52:34-43.

Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23.

Chayama K, Hayes CN, Hiraga N, Abe H, Tsuge M, Imamura M. Animal model for study of human hepatitis viruses. J Gastroenterol Hepatol 2011;26:13-8.

Chen HS, Kaneko S, Girones R, et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993;67:1218-26.

Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-27.

Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris);58:258-66.

Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr Opin Mol Ther 2003;5:148-55.

Dandri M, Lütgehetmann M, Petersen J. Experimental models and therapeutic approaches for HBV. Seminar Immunopathol 2013; 35(1):7-21.

Dandri M, Burda MR, Burkle A, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002;35:217-23.

Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8.

Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-46.

Dandri M, Burda MR, Zuckerman DM, et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 2005;42:54-60.

Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61: i6-i17.

Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? Hepatology 2005;42:1453-5.

Dandri M, Schirmacher P, Rogler CE. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol 1996;70:5246-54.

Daub H, Blencke S, Habenberger P, et al. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J Virol 2002;76:8124-37.

Decorsiere A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor Nature. 2016; 17;531(7594):386-9.

Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro . Antimicrob Agents Chemother 2002;46:425-33.

Drexler JF, Geipel A, König A, et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci USA 2013;110:16151-6.

Engelke M, Mills K, Seitz S, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 2006;43:750-60.

Fletcher SP, Chin DJ, Gruenbaum L, et al. Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. PLOS Pathogens 2015; 11(9):e1005103.

Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40:790-2.

Funk A, Mhamdi M, Will H, Sirma H. Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism. World J Gastroenterol 2007;13:91-103.

Gagneux P, Muchmore EA. The chimpanzee model: contributions and considerations for studies of hepatitis B virus. Methods Mol Med 2004;96:289-318.

Giersch K, Allweiss L, Volz T, Dandri M, Lütgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity J Hepatol 2016; S0168-8278(16)30641-9.

Giersch K, Helbig M, Volz T et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J. Hepatol 2014;60:538-44.

Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005;129:234-45.

Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007;13:22-38.

Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79:1613-22.

Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655-60.

Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.

Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 2010;14:e941-53.

Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-41.

Harrison TJ. Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 2006;26:87-96.

He W, Ren B, Mao F, et al. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Cotransporting Polypeptide. PLOS Pathogens 2015; 11(4):e1004840.

Hiraga N, Imamura M, Hatakeyama T, et al. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol 2009;51:1046-54.

Hoffmann J, Boehm C, Himmelsbach K, et al. Identification of alpha-taxilin as an essential factor for the life cycle of hepatitis B virus. J Hepatol 2013;59:934-941.

Iavarone M, Trabut JB, Delpuech O, et al. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol 2003;39:253-61.

Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 1996;226:338-45.

Kann M, Gerlich WH. Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. J Virol 1994;68:7993-8000.

Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol 1999;145:45-55.

Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.

Kim SH, Shin YW, Hong KW, et al. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antiviral Res 2008;79:188-91.

Kock J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsacker F. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001;75:5084-9.

Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, Thoma C. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 2010;6:e1001082.

Königer C, Wingert I, Marsmann M et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A 2014;111:E4244-53.

Korba BE, Cote PJ, Menne S, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 2004;9:937-52.

Korba BE, Cote PJ, Wells FV, et al. Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues. J Virol 1989;63:1360-70.

Lanford RE, Chavez D, Brasky KM, Burns RB, Rico-Hesse R. Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A 1998;95:5757-61.

Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55:762-9.

Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44:694-702.

Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011;85:11916-27.

Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92.

Li H, Zhuang Q, Wang Y, et al. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cellular & molecular immunology 2014;

Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010;15 Suppl 3:25-33.

Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S303-9.

Lu M, Roggendorf M. Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model. Intervirology 2001;44:124-31.

Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011;55:996-1003.

Lucifora, J.; Xia, Y.; Reisinger, F. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-28.

Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13:74-81.

Lutgehetmann M, Bornscheuer T, Volz T, et al. Hepatitis B Virus Limits Response of Human Hepatocytes to Interferon-alpha in Chimeric Mice. Gastroenterology 2011; 140(7):2074-83.

Lutgehetmann M, Mancke LV, Volz T, et al. Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012;55(3):685-94.

Lutgehetmann M, Volz T, Kopke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.

Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008;13:57-66.

Lutwick LI, Robinson WS. DNA synthesized in the hepatitis B Dane particle DNA polymerase reaction. J Virol 1977;21:96-104.

Mason WS, Aldrich C, Summers J, Taylor JM. Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA. Proc Natl Acad Sci U S A 1982;79:3997-4001.

Mason WS, Cullen J, Moraleda G, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998;245:18-32.

Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005;102:1139-44.

Mason WS, Seal G, Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980;36:829-36.

McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55.

Meier A, Mehrle S, Weiss TS, et al. Myristoilated preS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatol 2013; 58:31-42.

Melegari M, Wolf SK, Schneider RJ. Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression. J Virol 2005;79:9810-20.

Menne S, Cote PJ, Korba BE, et al. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 2005;49:2720-8.

Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.

Murphy CM, Xu Y, Li F,et al. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication Cell Rep. 2016; 13;16(11):2846-54.

Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A 2005;102:17780-5.

Nassal M.HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015; 64: 1972-84.

Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-7.

Nkongolo S, Ni Y, Lempp F. et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J.Hepatol. 2014 Apr;60(4):723-31.

Oehler N, Volz T, Bhadra OD et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology 2014;60:1483-93.

Ogata N, Cote PJ, Zanetti AR, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999;30:779-86.

Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007;132:1476-94.

Petersen J, Dandri M, Gupta S, Rogler CE. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1998;95:310-5.

Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26(3):335-41.

Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122-32.

Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J Virol 2010;84:7174-84.

Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009;286:80-8.

Pult I, Netter HJ, Bruns M, et al. Identification and analysis of a new hepadnavirus in white storks. Virology 2001;289:114-28.

Quasdorff M, Hosel M, Odenthal M, et al. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol 2008;10:1478-90.

Rabe B, Glebe D, Kann M. Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol 2006;80:5465-73.

Reaiche GY, Le Mire MF, Mason WS, Jilbert AR. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis. Virology 2010;406:286-92.

Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.

Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994;263:1149-52.

Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007;13:14-21.

Schmitt S, Glebe D, Tolle TK, et al. Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus. J Gen Virol 2004;85:2045-53.

Schmitz A, Schwarz A, Foss M, et al. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog 2010;6:e1000741.

Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007;46:1759-68.

Schulze A, Mills K, Weiss TS, Urban S. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology 2011.

Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2010;84:1989-2000.

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimation of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-55.

Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986;232:477-84.

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112-25.

Slagle BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996;15:261-9.

Sprengel R, Kaleta EF, Will H. Isolation and characterization of a hepatitis B virus endemic in herons. J Virol 1988;62:3832-9.

Summers J, Jilbert AR, Yang W, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 2003;100:11652-9.

Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analogue therapy. Proc Natl Acad Sci U S A 2004;101:638-40.

Summers J, Smith PM, Huang MJ, Yu MS. Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. J Virol 1991;65:1310-7.

Summers J, Smolec JM, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci U S A 1978;75:4533-7.

Summers J. The replication cycle of hepatitis B viruses. Cancer 1988;61:1957-62.

Tennant BC, Baldwin BH, Graham LA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998;28:179-91.

Tennant BC, Toshkov IA, Peek SF, et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004;127(5 Suppl 1):S283-93.

Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.

Tropberger P, Mercier A, Robinson M et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA 2015; 112:E5715-24.

Tsuge M, Hiraga N, Akiyama R, et al. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol 2010;91:1854-64.

Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005;42:1046-54.

Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterol 2014; 147(1): 48-64.

Visvanathan K, Lewin SR. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis 2006;26:104-15.

van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66-76.

Volz T Allweiss L, Ben MBarek M et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol 2013; 58:861-7.

Volz T, Lutgehetmann M, Wachtler P, et al. Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low viraemia in Most HBeAg-Negative Patients. Gastroenterology 2007;133:843-52.

von Weizsacker F, Kock J, MacNelly S, Ren S, Blum HE, Nassal M. The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes. Methods Mol Med 2004;96:153-61.

Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996;24:1-5.

Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound J Hepatol 2016; 65(4):700-10.

Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP. Hepatology 2013 doi: 10.1002/hep.26982.

Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.

Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101:6669-74.

Will H, Cattaneo R, Koch HG, et al. Cloned HBV DNA causes hepatitis in chimpanzees. Nature 1982;299:740-2.

Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-37.

Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175:255-61.

Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84.

Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife. 2012;1:e00049. doi: 10.7554/eLife.00049. Epub 2012 Nov 13.

Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH. Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J Cancer Res Clin Oncol 1996;122:283-8.

Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J Cancer Res Clin Oncol 1996;122:289-95.

Yang B, Bouchard MJ. The Hepatitis B Virus X Protein Elevates Cytosolic Calcium Signals by Modulating Mitochondrial Calcium Uptake. J Virol 2011.

Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci U S A 2003;100:12372-7.

Zhang Z, Protzer U, Hu Z, Jacob J, Liang TJ. Inhibition of cellular pro-teasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol 2004;78:4566-72.

Zhang Z, Torii N, Hu Z, Jacob J, Liang TJ. X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. J Clin Invest 2001;108:1523-31.

Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008;82:8013-21.

Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608 e1-2.

Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994;68:2026-30.

Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994;68:6-13.

Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol 2006;44 Suppl 1:S95-9.

Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 2005;55:608-11.

Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-8.

Hepatology 2018

Table of contents
Contributing authors
Free PDF Download

The Editors

Stefan Mauss
Thomas Berg
Juergen Rockstroh
Christoph Sarrazin
Heiner Wedemeyer

English language and style

Simon Collins



Privacy policy

© 2018 by Mauss, et al.